"Once NNLX has sufficient funds...." "Thought funds where to be used for expansion and N Assay development."
The penny companies which survive are often those who carefully watched costs. From everything I've seen NNLX has been carefully watching costs until presumably net income is achieved-a landmark event for these low pennies.
From that point of view NNLX may consider it unnecessary at present to pay 4200/year plus possibly some additional accounting expenses to upgrade to otc current pink or 10,000/year plus additional accounting to upgrade to OTCQB. Once a patent is sold for any meaningful amount of money whatsoever, the costs to upgrade should be considered negligible, especially if NNLX wants pps to rise to raise additional funds or for other reasons.
I haven't researched to refresh my memory the timeline of Hank as VP of sales vs the 400% rise in revenue yoy for the last 2 years of posted revenues,but somebody else could easily do that research.
Its not just a matter of salesmanship but the ability to break through entrenched vendor relationships which are controlled by inertia plus politics plus money. So its not always enough to demonstrate a superior product-value has to be shown to offset current vendor relationships. Such value would include showing that hospital legal fees would be reduced by buying a product which can save peoples lives vs their present inferior product. But its hard to do that until some critical industry mass can be demonstrated to show that the hospital or other entity that doesn't use the superior product is endangering their clients/patients.
So the salesman also has to be part visionary. It's probably not hard to gather the evidence to show the superiority of NNLX's products,but again that is often not initially sufficient when confronting politics and inertia etc. Very few humans are visionary-most are content to contemplate their navel rather than change course or do something original. Visionaries are usually met by a huge wall of jealous etc opposition and the value of their visions/breakthroughs etc often are recognized only posthumously.
The penny companies which survive are often those who carefully watched costs. From everything I've seen NNLX has been carefully watching costs until presumably net income is achieved-a landmark event for these low pennies.
From that point of view NNLX may consider it unnecessary at present to pay 4200/year plus possibly some additional accounting expenses to upgrade to otc current pink or 10,000/year plus additional accounting to upgrade to OTCQB. Once a patent is sold for any meaningful amount of money whatsoever, the costs to upgrade should be considered negligible, especially if NNLX wants pps to rise to raise additional funds or for other reasons.
I haven't researched to refresh my memory the timeline of Hank as VP of sales vs the 400% rise in revenue yoy for the last 2 years of posted revenues,but somebody else could easily do that research.
Its not just a matter of salesmanship but the ability to break through entrenched vendor relationships which are controlled by inertia plus politics plus money. So its not always enough to demonstrate a superior product-value has to be shown to offset current vendor relationships. Such value would include showing that hospital legal fees would be reduced by buying a product which can save peoples lives vs their present inferior product. But its hard to do that until some critical industry mass can be demonstrated to show that the hospital or other entity that doesn't use the superior product is endangering their clients/patients.
So the salesman also has to be part visionary. It's probably not hard to gather the evidence to show the superiority of NNLX's products,but again that is often not initially sufficient when confronting politics and inertia etc. Very few humans are visionary-most are content to contemplate their navel rather than change course or do something original. Visionaries are usually met by a huge wall of jealous etc opposition and the value of their visions/breakthroughs etc often are recognized only posthumously.
1
